How Long Does Sermorelin Take to Work?

Sermorelin raises growth hormone within minutes of an injection, and in studies of older adults a blood marker called IGF-1 rose within about 2 weeks. Changes you could actually notice took far longer. In the small trials that exist, measurable gains in lean mass appeared only after roughly 3 to 6 months of nightly use, they were modest, and sleep did not improve at all. As of September 2026, no FDA-approved sermorelin product is sold in the United States, so what is prescribed today comes from compounding pharmacies or third-party-tested peptide suppliers, neither of which is FDA reviewed, and its use for age-related hormone decline has never been approved.

The short answer, in three layers

"How long does it take to work" has three different answers, because sermorelin does three different things on three different clocks. Mixing them up is the main reason people end up either disappointed or oversold.

1. The hormone signal: minutes. Sermorelin tells your pituitary gland to release a pulse of growth hormone (GH). The drug itself is gone quickly. The former prescribing information for Geref, as reproduced by the drug reference RxList (no FDA-hosted copy of the discontinued label could be found for this guide), lists a half-life of 11 to 12 minutes and peak blood levels 5 to 20 minutes after an injection under the skin.
2. The blood marker: about 2 weeks. GH tells the liver to make insulin-like growth factor 1 (IGF-1), a steadier hormone that doctors use as a readout of the whole system. In a 16-week study of adults aged 55 to 71 given a close analog of sermorelin, IGF-1 was significantly higher within 2 weeks of starting nightly injections.
3. The body: months, and modestly. Changes in lean mass, body fat, skin thickness, or test scores were measured after 3 to 6 months in the studies that found them. Several outcomes people hope for, including better sleep and clear gains in strength, did not show up reliably at any time point.

The rest of this guide walks through each layer, names the studies behind it, and is plain about how small and how old most of those studies are. If you are comparing sermorelin with growth hormone itself, the companion guide on sermorelin versus HGH covers that question in detail.

Regulatory status as of September 2026

This matters before any timeline does, because it determines what you are actually being given.

Sermorelin was FDA approved, then discontinued

Sermorelin acetate was sold in the United States under the brand name Geref. According to the FDA's notice in the Federal Register, a low-dose ampule was approved on December 28, 1990 as a diagnostic agent, to test whether the pituitary gland could secrete growth hormone. Larger vials were approved on September 26, 1997 to treat idiopathic growth hormone deficiency in children with growth failure. Neither approval covered adults, and neither covered age-related hormone decline.

The manufacturer told the FDA in 2008 that it was discontinuing both products, and the withdrawal of approval took effect on June 18, 2009. On March 4, 2013, the FDA published its formal determination that Geref was not withdrawn from sale for reasons of safety or effectiveness. A 2006 editorial in Clinical Interventions in Aging, an opinion piece written before the formal US discontinuation, had already described sermorelin as a product that could not compete with recombinant growth hormone in children. The FDA notice itself gives no commercial reason.

What is prescribed today is not FDA reviewed

As of September 2026, there is no FDA-approved sermorelin product on the US market. What is dispensed today comes by one of two routes: compounding pharmacies, which prepare it on a prescription, or peptide suppliers that sell third-party-tested product with a certificate of analysis, which a physician then reconstitutes and dispenses. Neither route is FDA reviewed. The FDA states plainly that compounded drugs are not FDA approved, which means the agency does not verify their safety, effectiveness, or quality before they reach you, and it warns that poor compounding practices can produce contaminated products or products with too much or too little active ingredient. Supplier-sourced peptide is not FDA verified either; its quality rests on the independent laboratory testing behind each batch.

One point of context: the FDA keeps a public list of bulk drug substances that it believes may present significant safety risks when compounded. As of that page's April 22, 2026 update, the list includes several other growth hormone releasing peptides, such as ipamorelin, GHRP-2, and GHRP-6, with a note about the risk of immune reactions from peptide impurities. Sermorelin does not appear on that list. That is not the same thing as an FDA endorsement. It means only that the agency has not flagged it there.

Rx2BFIT sources its sermorelin from a supplier whose batches are tested by an independent laboratory for identity and purity, keeps the certificate of analysis on file, and reconstitutes it in the office under Dr. Patel's supervision. It is not an FDA-approved medication, and that, along with the known risks and the limits of the evidence, is reviewed with every patient before starting.

Banned in sport

The World Anti-Doping Agency's 2026 Prohibited List, in force since January 1, 2026, names sermorelin specifically. It sits in section S2.2.4, growth hormone releasing factors, alongside tesamorelin and CJC-1295, in the part of the list that is prohibited at all times, in and out of competition. If you compete in a tested sport, a prescription does not change that without a formal therapeutic use exemption.

How sermorelin works, and why the clock starts slowly

Your brain controls growth hormone with two opposing signals from the hypothalamus. Growth hormone releasing hormone (GHRH) says "release." Somatostatin says "stop." The pituitary gland, a pea-sized gland under the brain, responds by releasing GH in bursts rather than a steady stream, with much of the release tied to nighttime sleep.

Natural GHRH is a chain of 44 amino acids. Sermorelin is the first 29 of them. A published drug review describes it as the shortest synthetic fragment that keeps the full biological activity of GHRH. It binds the same receptor on the pituitary and triggers the same release.

A signal, not a supply

This is the key difference from injecting growth hormone. Sermorelin does not add GH to your blood. It asks your own pituitary to release what it has made, and the usual brakes stay on. Somatostatin and rising IGF-1 both feed back to limit the response. Researchers have argued that this makes a large overdose of GH hard to achieve with a GHRH analog, and that the release stays pulsatile instead of flat.

That safety logic is also the reason sermorelin is slow and its effects are small. Each injection produces one short-lived pulse from a drug with a half-life of 11 to 12 minutes. The total GH exposure over a day rises, but not dramatically, and tissue-level change depends on that modest rise being repeated night after night for months.

Why growth hormone falls with age in the first place

GH secretion drops by roughly 15 percent per decade after your twenties, according to the Endotext clinical reference, mostly because nighttime pulses get smaller, not less frequent. Two careful experiments from the University of Michigan help explain why. In healthy older men, nighttime GH was about 30 percent lower than in young men, yet their pituitaries responded to injected GHRH just as well. The researchers concluded that the aging hypothalamus sends less GHRH, while the pituitary remains capable.

That finding is the scientific rationale for sermorelin in older adults: replace the missing signal and the gland should answer. It is a reasonable hypothesis. Interestingly, the same group did not find a measurable drop in GHRH output in older women, which suggests the mechanism of decline differs by sex, and may be one reason study results in men and women have not matched.

What the studies in older adults actually measured

Here is the uncomfortable part. The entire evidence base for sermorelin and closely related GHRH peptides in aging adults consists of a handful of small studies, most from the 1990s and early 2000s, most lasting 2 to 26 weeks, and several with no placebo group. There are no large randomized trials, and none that followed people for years. A 2003 review by three of the field's leading investigators said that all studies to date had been small ones aimed at intermediate endpoints, and concluded that the results did not yet support routine use in normal aging. No large trial appears to have been published since to change that conclusion.

With that framing, these are the studies worth knowing.

Two weeks: hormones move (Corpas and colleagues, 1992)

Researchers at the National Institute on Aging gave 10 healthy men, average age 68, injections of GHRH (1-29), the sermorelin peptide, twice a day for 14 days at two dose levels, and compared them with 9 men in their twenties. At the start, the older men had significantly lower IGF-1. After 14 days at the higher dose, their 24-hour GH levels, GH peak size, and IGF-1 had all risen significantly, to the point that they no longer differed statistically from the young men. At the lower dose, the changes were not significant.

Two things stand out. First, the hormone response is fast: two weeks was enough. Second, dose and frequency mattered, and this study used twice-daily dosing, which is not how sermorelin is typically prescribed today. The study did not measure body composition, strength, or how anyone felt.

Six weeks: a single nightly dose underwhelms (Vittone and colleagues, 1997)

A Johns Hopkins team treated 11 healthy men aged 64 to 76, all with low IGF-1 at baseline, with one nightly self-injection of GHRH (1-29) for 6 weeks. There was no placebo group. Nighttime GH release rose significantly. IGF-1 did not change. Neither did weight, waist to hip ratio, muscle or fat on DEXA scanning, muscle biopsy findings, glucose, insulin, or cholesterol.

Two of six strength measures and one endurance measure improved, which the authors reported cautiously given the lack of a control group. Their own conclusion was that a single nightly dose appeared less effective than multiple daily doses at producing GH and IGF-1 mediated effects. For anyone expecting visible change at 6 weeks, this is the most relevant study, and its answer is: probably not.

Sixteen weeks: the most cited trial (Khorram and colleagues, 1997)

This is the study most often quoted in sermorelin marketing, so it is worth reading closely. Nineteen adults aged 55 to 71 (10 women and 9 men) injected a placebo nightly for 4 weeks, then a GHRH analog nightly for 16 weeks. The design was single-blind, meaning the participants did not know which phase they were in, but the researchers did. The peptide used was a sermorelin variant with one amino acid swapped, so it is a very close relative, not the identical molecule.

What happened, and when:

• Growth hormone: 12-hour overnight GH levels rose significantly in both women and men.
• IGF-1: significantly higher within 2 weeks. It stayed elevated through week 12 and was returning toward baseline by week 16, a hint that the response may fade with continued use.
• Skin thickness: increased significantly in both sexes by the end of treatment.
• Lean body mass: increased significantly in men only. The trial's abstract gives no figure. A 2020 peer-reviewed review of the trial reports the gain as 1.26 kg. Women showed no significant change.
• Body fat and body weight: no change in either sex.
• Insulin sensitivity: improved in men, not in women.
• Well-being and libido: men reported significant improvement in both. Women did not.
• Sleep quality: unchanged in both sexes.
• Side effects: the only one reported was a temporary rise in blood lipids that resolved by the end of the study.

A gain of 1.26 kg of lean mass over 16 weeks in 9 men is a real finding, but a small one from a small group. Lean mass on a scan also includes water, and GH causes fluid retention, so not all of that gain is necessarily muscle. The self-reported improvements in well-being came from a design in which everyone knew they would eventually receive the active drug.

Five to six months: body composition and thinking (the Seattle studies)

The longest sermorelin work came from the University of Washington. According to the Endotext summary of that program, and a 2008 review written by one of its lead investigators, 6 months of bedtime sermorelin injections, alone or combined with exercise, raised IGF-1 by about 35 percent. A full peer-reviewed report of those body composition results could not be located for this guide, so treat the figure as approximate. Lean mass increased and body fat decreased, mainly deep abdominal fat. Strength and aerobic fitness did not improve.

The cognitive arm of that work was placebo controlled and is the strongest single piece of sermorelin evidence. The published abstract describes the drug only as GHRH. The Endotext reference, co-written by one of the trial's investigators, identifies it as sermorelin acetate. Among 89 healthy adults with an average age of 68, those given daily GHRH for 6 months scored better than the placebo group on several tests of fluid thinking, including a performance IQ measure, a picture arrangement task, and tests of processing speed and working memory. Tests of stored knowledge did not change. The benefits did not depend on sex or on baseline ability.

This is encouraging, and it has not been replicated with sermorelin at scale. A later trial from the same group used tesamorelin, a stabilized GHRH analog that is FDA approved for a different purpose, in 152 adults aged 55 to 87, 66 of whom had mild cognitive impairment, for 20 weeks. It found a favorable effect on executive function, a 117 percent rise in IGF-1, and a 7.4 percent reduction in body fat percentage. Mild adverse events were reported by 68 percent of the treated group versus 36 percent on placebo. Tesamorelin is a different drug, so those numbers should not be transferred to sermorelin. The guide on tesamorelin and visceral fat covers that drug's evidence.

Three months at high dose: a different GHRH peptide

One more study is often cited for sermorelin and should not be. A Mayo Clinic team gave 10 postmenopausal women full-length GHRH (the 44 amino acid form) twice daily for 3 months, with no control group. Overnight GH roughly doubled at both 1 and 3 months, IGF-1 rose 71 percent from week 2 onward, abdominal visceral fat fell 16 percent, and walking and stair-climbing times improved. Seven of the 10 women had skin reactions at the injection site.

It supports the general idea that GHRH-type drugs can shift body composition within 3 months at high, twice-daily doses. It does not tell you what a once-nightly sermorelin prescription will do.

A realistic timeline, study by study

Putting those results on one calendar gives the most honest answer available. Every row below comes from small studies, and your own response may be slower, smaller, or absent.

What this means in practice

If a blood test is the yardstick, a prescriber can reasonably look for an IGF-1 response within the first month or two. If the yardstick is how you look, feel, or perform, the research supports waiting at least 3 months, and more realistically 6, before judging. It also supports the possibility that the honest verdict at 6 months is "not much." Most of the dramatic week-by-week timelines you will find online, with better sleep in week 1 and fat loss by week 4, are not drawn from any of these studies.

Why sermorelin is usually injected at night

Nearly every study above used bedtime dosing, and so did the Geref prescribing information for children. The reasoning is physiological, though the payoff is less proven than it sounds.

Growth hormone and deep sleep travel together

Growth hormone release is closely tied to sleep, and in particular to slow wave sleep, the deepest stage. The age-related fall in GH comes mainly from smaller nighttime pulses. A University of Chicago analysis of 149 healthy men aged 16 to 83 showed how tightly the two are linked. Slow wave sleep fell from 18.9 percent of the night in early adulthood to 3.4 percent by midlife, and GH secretion fell in parallel over the same years. Independent of age, men with more slow wave sleep secreted more GH.

A bedtime injection is meant to land on top of that natural window, amplifying the pulse your body was already going to produce instead of creating one at an odd hour.

Does it improve sleep? The trials say no

Because GHRH given by vein promotes deep sleep in short laboratory experiments, many people expect sermorelin to fix their sleep, and quickly. The longer studies do not back this up. Sleep quality was unchanged after 16 weeks in the Khorram trial. The Seattle investigators reported that chronic treatment with short-acting GHRH did not improve sleep, and suggested that a drug lasting minutes cannot sustain an effect across a whole night. The Endotext reference reaches the same conclusion across the literature: most studies giving GH or GHRH to older adults did not improve slow wave sleep.

If sleep is your main goal, the evidence points elsewhere. The relationship may even run mostly in the other direction, with better sleep supporting better GH release.

Factors that can blunt or delay a response

Sermorelin only works if your pituitary can answer and nothing is holding the brake down. Several well-documented factors reduce the response.

Body fat, especially around the abdomen

Obesity is associated with lower GH secretion. Endotext describes abdominal visceral fat as the best predictor of reduced GH secretion in humans, and notes that higher body fat lowers IGF-1 independent of age. In practical terms, the people most drawn to sermorelin for body composition are often the people whose pituitary response to it is most muted.

Thyroid function

The Geref prescribing information reported that hypothyroidism developed in 6.5 percent of patients during clinical studies, and warned that untreated hypothyroidism can jeopardize the response. It advised checking thyroid function before and during therapy. An underactive thyroid is common in adults, so this is worth knowing.

Glucocorticoid medications

The same label states that glucocorticoids, such as prednisone, may inhibit the response to sermorelin. If you take steroid medication regularly, your prescriber needs to know.

Dose frequency

The contrast between the Corpas study (twice daily, IGF-1 normalized in 2 weeks) and the Vittone study (once nightly, no IGF-1 change at 6 weeks) suggests that a single nightly injection is a relatively weak stimulus. The Vittone authors said so directly. This is a research observation, not a suggestion to change your dosing. Dose decisions belong to your prescriber.

Sex and hormone status

In the Khorram trial, lean mass, insulin sensitivity, well-being, and libido improved in men but not in women, even though GH rose in both. Estrogen status, body composition, and sex differences in how GH decline happens may all play a part. Older adults also differ in sex hormone levels, and Endotext notes that falling testosterone in men and estradiol in women are each linked with lower GH output.

A pituitary that cannot respond

Sermorelin needs a working pituitary. People whose GH deficiency comes from pituitary damage, surgery, or radiation may not respond at all. The Geref label advised against treatment in patients with intracranial lesions, and the prescribing information for tesamorelin, the related approved drug, lists disruption of the hypothalamic-pituitary axis as a contraindication.

Product quality

Because no sermorelin sold today is FDA reviewed, whether it comes from a compounding pharmacy or a peptide supplier, potency is not verified by the FDA. Independent batch testing with a certificate of analysis speaks to identity and purity at the time of testing, not to what happens to a vial afterward. A peptide that was under-dosed, stored warm, or degraded after mixing will produce a weaker response or none. The Geref label called for refrigerated storage. A flat IGF-1 after several months can reflect the product as easily as it reflects your biology.

Antibodies

The Geref label noted that a large proportion of treated children developed antibodies to the peptide at least once. In those pediatric studies the antibodies often disappeared on later testing and did not appear to affect growth or side effects. Whether antibodies matter in adults using sermorelin long term has not been studied.

What is realistic, and what is not

Reasonable expectations

• A measurable rise in IGF-1 within the first several weeks, if your pituitary responds and the product is potent.
• Possibly a modest shift in body composition after 3 to 6 months: roughly a kilogram or so of lean mass in men in the one 16-week analog trial with a reported figure, and some reduction in abdominal fat in the 6-month work.
• Possibly small improvements on tests of processing speed and problem solving after 6 months, based on one placebo-controlled trial of 89 people.

Expectations the evidence does not support

• Noticeably better sleep. The trials that measured it found no change.
• Meaningful weight loss. Body weight did not change in any of the studies above.
• Clear gains in strength or fitness. The 6-month studies found none, and the 6-week study found partial changes without a control group.
• Rapid visible results. Nothing was detectable on a body scan at 6 weeks.
• Proven anti-aging benefit. No study has tested whether sermorelin helps people live longer, stay independent longer, or avoid disease.

How this compares with growth hormone itself

For perspective, a Stanford systematic review pooled randomized trials of actual growth hormone in healthy older adults: 220 treated participants, average age 69, treated for an average of 27 weeks. GH reduced fat mass by about 2.1 kg and raised lean mass by about 2.1 kg, with no change in weight. It also significantly increased swelling, joint pain, carpal tunnel syndrome, and breast enlargement in men, with a trend toward more diabetes. The authors concluded GH could not be recommended as an anti-aging therapy, and noted that distributing it for that purpose is illegal in the United States.

Sermorelin is a gentler stimulus than GH. It is fair to expect its benefits to be smaller than those figures, and its side effects to be milder. Both halves of that sentence matter.

A caution about the goal itself

It is not settled that raising GH and IGF-1 in later life is a good idea. A 2025 clinical review points out that in several mouse models, lower GH and IGF-1 signaling is linked with longer life, and that people with Laron syndrome, who have very low IGF-1, show an almost complete absence of cancer. That does not prove that restoring youthful IGF-1 is harmful. It does mean the age-related decline might be partly protective, and that "low for a 30 year old" is not automatically a deficiency in a 65 year old.

Side effects and safety

What the prescribing information reported

The Geref label data come mainly from children with GH deficiency, but they are the best safety data that exist for this molecule. The figures below are taken from RxList's reproduction of the discontinued label, not from an FDA-hosted copy. Of 350 patients exposed, the most common treatment-related problem was a local injection reaction (pain, swelling, or redness), which occurred in about 1 patient in 6. Only 3 patients stopped treatment because of it.

Other treatment-related events were each reported in fewer than 1 percent of patients: headache, flushing, difficulty swallowing, dizziness, hyperactivity, sleepiness, and hives. When sermorelin was given by vein for diagnostic testing, the label also noted facial flushing, nausea, vomiting, headache, altered taste, pallor, and chest tightness, without giving frequencies. A published drug review likewise names transient facial flushing and injection site pain as the most common complaints.

What the adult studies reported

The adult aging studies were small, so they can only detect common problems. The 16-week trial reported temporary elevated blood lipids. The 6-week study reported no significant adverse effects. The twice-daily study found no change in fasting glucose, blood pressure, or routine blood chemistry over 14 days. In the high-dose GHRH study in women, 70 percent had local skin reactions.

Class effects to watch for

Anything that raises GH and IGF-1 can, in principle, cause the effects seen with GH itself. No such warnings exist for sermorelin itself, so the ones below are borrowed from a different drug: tesamorelin, a GHRH analog approved only for reducing abdominal fat in adults with HIV. Its FDA label warns about fluid retention (swelling, joint pain, carpal tunnel symptoms), glucose intolerance and new diabetes, and elevated IGF-1. It recommends monitoring IGF-1 and blood sugar during therapy, and states that the effects of prolonged IGF-1 elevation are unknown. In tesamorelin's trials, 5 percent of treated patients reached a diabetic-range HbA1c compared with 1 percent on placebo.

Those figures belong to a different drug in a different population, people with HIV. They are not sermorelin numbers. They are the reason a careful prescriber checks IGF-1 and glucose instead of assuming a "natural" peptide needs no monitoring.

Long-term safety is unknown

The longest controlled sermorelin exposure in aging adults is about 6 months. A review of growth hormone secretagogues in a sexual medicine journal concluded that these drugs appear well tolerated in available studies, with some concern about rising blood glucose, and that long-term work including cancer incidence and mortality is still needed. Nobody can currently tell you what 5 or 10 years of nightly sermorelin does.

When to seek urgent care

Get emergency help for signs of a serious allergic reaction after an injection: hives spreading over the body, swelling of the face, lips, or throat, trouble breathing or swallowing, or chest tightness. Contact your prescriber promptly for persistent swelling in the hands or feet, new numbness or tingling in the fingers, new joint pain, unusual thirst or frequent urination, or an injection site that becomes hot, increasingly painful, or drains fluid.

Who should not use sermorelin

No current FDA label governs sermorelin in adults, so this list draws on the former Geref label and on the label for tesamorelin, a different GHRH analog approved only for adults with HIV-related abdominal fat. The tesamorelin items are borrowed by analogy and were never established for sermorelin. Your prescriber makes the final call.

• Active cancer. Tesamorelin is contraindicated in active malignancy because GH and IGF-1 are growth signals. Its label says any previous cancer should be inactive, with treatment complete, before starting.
• Pregnancy. Geref carried a pregnancy category C rating, to be used only if the benefit justified the risk. Tesamorelin is contraindicated in pregnancy outright. The Geref label said it was not known whether sermorelin passes into breast milk.
• Pituitary or hypothalamic disease, or an intracranial lesion. The Geref label advised against use, and the drug may simply not work.
• Known allergy to sermorelin or to any ingredient in the product as supplied or reconstituted.
• Untreated hypothyroidism. It blunts the response and should be corrected first.
• Uncontrolled diabetes. GH opposes insulin. The tesamorelin label calls for glucose evaluation before and during treatment.
• Acute critical illness. The tesamorelin label notes increased mortality when growth hormone was given to critically ill patients after major surgery or trauma, and advises considering discontinuation.
• Athletes subject to drug testing. Sermorelin is prohibited at all times under the 2026 WADA list.

Children are a separate case. Geref was approved for pediatric GH deficiency, but it is no longer made, and a child with growth failure needs a pediatric endocrinologist, not a wellness peptide.

Myths versus realities

Myth: you will sleep better within days

Reality: a 16-week trial and the 5 to 6 month Seattle studies both found no improvement in sleep. If sleep improves in the first week, the most likely explanations are expectation and the other changes people tend to make when they start a new health program.

Myth: sermorelin is just a safer form of HGH with the same results

Reality: it preserves feedback control, which is a real safety advantage in theory, but it also produces a smaller effect. No trial has compared sermorelin head to head with GH in aging adults. In children, a published drug review noted that the recommended sermorelin dose was never directly compared with GH, and that growth responses with other sermorelin dosing schedules were smaller than those seen with GH.

Myth: it is FDA approved, so the product is vetted

Reality: the molecule was approved for one treatment use in children and as a diagnostic agent, the brand was discontinued, and the approval was withdrawn at the manufacturer's request effective 2009. No sermorelin product sold in the US today has been reviewed by the FDA.

Myth: it works better when stacked with other peptides

Reality: sermorelin is often paired with ghrelin-type peptides such as ipamorelin. The published human support is thin. One retrospective chart review of 14 men on testosterone who also took sermorelin with GHRP-2 and GHRP-6 found higher IGF-1 at follow-up, with no body composition data and no comparison group. Several of those companion peptides are on the FDA's list of bulk substances that may present significant safety risks when compounded. The guide to ipamorelin and growth hormone secretagogues goes deeper.

Myth: if IGF-1 goes up, it is working

Reality: IGF-1 tells you the pituitary responded. It does not tell you that you gained muscle, lost fat, or will age better. In the Khorram trial, women had the same hormonal rise as men and none of the body composition benefit.

Myth: results keep building the longer you stay on it

Reality: nobody knows. IGF-1 drifted down between weeks 12 and 16 in the one 16-week analog trial, and no controlled study runs past about 6 months.

Questions to ask your prescriber

• What is my baseline IGF-1, and is it actually low for my age, or just lower than a young adult's?
• Have you checked my thyroid function and fasting glucose or HbA1c before starting?
• What specific outcome are we tracking, how will it be measured, and at what point would you say it has not worked?
• How often will you recheck IGF-1 and blood sugar, and what IGF-1 level would make you reduce or stop?
• Where does this come from, a compounding pharmacy or a peptide supplier, and is each batch tested by an independent laboratory for identity, purity, and sterility, with a certificate of analysis I can see?
• How should I store it, and how long is it good for after mixing?
• Do any of my medications, particularly steroids, interfere with it?
• I have a personal or family history of cancer. How does that change your advice?
• Would changes to sleep, resistance training, or abdominal fat do more for my GH levels than this drug?

That last question is not rhetorical. In the research above, more deep sleep and less visceral fat were each tied to higher natural GH secretion, and neither carries the unknowns of a peptide that no regulator has reviewed. An overview of where this peptide sits among other options is on the sermorelin treatment page and in the broader section on healthy aging and wellness.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.